Expert Ratings For Biogen
Within the last quarter, Biogen (NASDAQ:BIIB) has observed the following analyst ratings:
Last 30 Days
1 Month Ago
2 Months Ago
Morgan Stanley Maintains Overweight on Biogen, Raises Price Target to $455
Morgan Stanley analyst Matthew Harrison maintains Biogen (NASDAQ:BIIB) with a Overweight and raises the price target from $453 to $455.
RBC Capital Maintains Sector Perform on Biogen, Lowers Price Target to $341
RBC Capital analyst Brian Abrahams maintains Biogen (NASDAQ:BIIB) with a Sector Perform and lowers the price target from $361 to $341.
Understanding Biogen’s Unusual Options Activity
Biogen (NASDAQ:BIIB) shares experienced unusual options activity on Wednesday. The stock price moved down to $322.07 following the option alert.
Alzheimer’s Approval, COVID-19 Vaccines Put Spotlight On Biotech Sector, But What’s Next?
For most of the past year, just a handful of companies carried the biotech sector, thanks to their quick responses to the COVID-19 pandemic.
Biogen, Mirimus Team Up For RNAi-Based Therapeutics For Neurological Indications
Mirimus Inc has collaborated with Biogen Inc (NASDAQ:BIIB) to develop RNAi-based therapeutics targeting multiple, undisclosed neurological disease indications. Terms of the…
Mirimus Reports Strategic Collaboration With Biogen, No Terms Disclosed
Mirimus, Inc., a pioneer in RNAi therapeutic design and CRISPR/Cas9 gene editing technology implementation, today announced a strategic collaboration with Biogen Inc. (NASDAQ:BIIB) focused on the development of
Carnival And American Airlines Lead The SPY Higher Tuesday
U.S. indices were trading higher Tuesday amid a rebound in reopening stocks, which dipped Monday amid Delta variant concerns.
The Week Ahead In Biotech: Earnings Kickstart With J&J And Biogen, Albireo Awaits FDA Decisions, More IPOs
Biotech stocks were down for a second week in a row, as they retreated along with the broader market amid macro concerns. Consumer price inflation data released during the week stoked rate hike fears, and exerted negative pressure on stocks.
There were very few stock-specific catalysts, barring a few preannouncements, stock offerings, and a slew of initial public offerings.